Inclusion Criteria:~1. Diagnosis of early stage Alzheimer's disease as scored by the ClinicalDementia Rating
Scale score of 0.5 -1.0 within the 6 months prior to study enrollment.~2. Participants able to provide informed
consent.~3. Participants taking NMDA receptor antagonist medications or acetylcholinesterase inhibitor
medications must be on a stable dose of these medications for at least 30 days prior to enrolling in this
clinical trial.~4. Participants able to consume study gummy chews throughout the course of the clinical trial.~
